Evidence map›Paper›PMID 36558835›Full record

ReviewPathogens (Basel, Switzerland)2022

Approximations to Diagnosis and Therapy of COVID-19 in Nervous Systems Using Extracellular Vesicles.

Karen Rojas, Maritza G Verdugo-Molinares, Andrea G Ochoa-Ruiz, Alejandro Canales, Edwin E Reza-Zaldivar, Areli Limón-Rojas, Alba Adriana Vallejo-Cardona

Open access · goldAbstract readReview
In one paragraph

Review in Pathogens (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 75% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Karen RojasMedical and Pharmaceutical Biotechnology Unit, Center for Research and Assistance in Technology and Design of the State of Jalisco, A.C. (CIATEJ), Av. Normalistas 800, Colinas de la Normal, Guadalajara C.P. 44270, Jalisco, Mexico.ORCID 0000-0002-6615-6310
Maritza G Verdugo-MolinaresMedical and Pharmaceutical Biotechnology Unit, Center for Research and Assistance in Technology and Design of the State of Jalisco, A.C. (CIATEJ), Av. Normalistas 800, Colinas de la Normal, Guadalajara C.P. 44270, Jalisco, Mexico.
Andrea G Ochoa-RuizMedical and Pharmaceutical Biotechnology Unit, Center for Research and Assistance in Technology and Design of the State of Jalisco, A.C. (CIATEJ), Av. Normalistas 800, Colinas de la Normal, Guadalajara C.P. 44270, Jalisco, Mexico.ORCID 0000-0001-9873-6144
Alejandro CanalesMedical and Pharmaceutical Biotechnology Unit, Center for Research and Assistance in Technology and Design of the State of Jalisco, A.C. (CIATEJ), Av. Normalistas 800, Colinas de la Normal, Guadalajara C.P. 44270, Jalisco, Mexico.ORCID 0000-0003-0918-788X
Edwin E Reza-ZaldivarTecnologico de Monterrey, Institute for Obesity Research, Av. General Ramón Corona 2514, Zapopan C.P. 45201, Jalisco, Mexico.ORCID 0000-0001-5702-9515
Areli Limón-RojasMedical and Pharmaceutical Biotechnology Unit, Center for Research and Assistance in Technology and Design of the State of Jalisco, A.C. (CIATEJ), Av. Normalistas 800, Colinas de la Normal, Guadalajara C.P. 44270, Jalisco, Mexico.
Alba Adriana Vallejo-CardonaMedical and Pharmaceutical Biotechnology Unit, CONACYT-Center for Research and Assistance in Technology and Design of the State of Jalisco, A.C., Av. Normalistas 800, Colinas de la Normal, Guadalajara C.P. 44270, Jalisco, Mexico.ORCID 0000-0002-4568-3787
Secretaría de Salud de Jalisco · MXTecnológico de Monterrey · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The SARS-CoV-2 virus was first identified at the end of December 2019, causing the disease known as COVID-19, which, due to the high degree of contagion, was declared a global pandemic as of 2020. The end of the isolation was in 2022, thanks to the global multidisciplinary work of the massive vaccination campaigns. Even with the current knowledge about this virus and the COVID-19 disease, there are many questions and challenges regarding diagnosis and therapy in the fight against this virus. One of the big problems is the so-called "long COVID", prolonged symptomatology characterized as a multiorgan disorder manifested as brain fog, fatigue, and shortness of breath, which persist chronically after the disease resolution. Therefore, this review proposes using extracellular vesicles (EVs) as a therapeutic or diagnostic option to confront the sequelae of the disease at the central nervous system level. Development: the review of updated knowledge about SARS-CoV-2 and COVID-19 is generally addressed as well as the current classification of extracellular vesicles and their proposed use in therapy and diagnosis. Through an analysis of examples, extracellular vesicles are highlighted to learn what happens in the central nervous system during and after COVID-19 and as a therapeutic option. Conclusions: even though there are limitations in the knowledge of the neurological manifestations of COVID-19, it is possible to observe the potential use of extracellular vesicles in therapy or as a diagnostic method and even the importance of their study for the knowledge of the pathophysiology of the disease.

Indexed as

COVID-19diagnosticextracellular vesicles (EVs)SARS-CoV-2therapy

Identifiers

PMID36558835
PMCPMC9782638
OpenAlexW4311961524

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.